Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The transcript discusses various business segments: diagnostics (BioReference), pharmaceuticals (RAYALDEE, Somatrogon), and the ModeX acquisition. The question is about the company's own repeatable business escalating in unit size. The transcript mentions growth in volumes, new contracts, but does it convey that each new deal is larger than previous ones? For example, BioReference's growth in noninvasive prenatal testing, oncology volumes, etc., but that's volume growth, not necessarily larger individual contracts. The ModeX acquisition is a one-time event, not a repeatable business. The Sema4 transaction is also a one-time deal. The Pfizer milestones are one-time. There is no mention of progressively larger deals or contracts. Management talks about expanding partnerships, adding hospitals, but not that each new hospital is larger than before. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size." The transcript does not contain such a statement. Management reports strong demand, more tests, more customers, but not that the individual size of engagements has grown. For example, they mention adding schools and ships, but not that each new school or ship is larger. They mention Teladoc partnership, but that's a single new partnership, not a series. No comparison against past deal sizes. So answer NO. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.